Phase Ia/Ib Study of RS-0139 in Patients with a Recurrent, Locally Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 13, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions

Solid Tumors

Interventions

DRUG

RS-0139

RS-0139 will be administered for the indication of solid tumors.

Trial Locations (2)

RECRUITING

Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi, Ankara

RECRUITING

Koç University Hospital Phase I Center, Istanbul

All Listed Sponsors

lead

RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.

INDUSTRY